# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

> **NCT03571828** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 10 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma(DLBCL)
- Mantle Cell Lymphoma (MCL)
- Follicular Lymphoma (FL)

## Interventions

- **DRUG:** AMG 562

## Key facts

- **NCT ID:** NCT03571828
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-29
- **Primary completion:** 2022-01-12
- **Final completion:** 2022-01-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Amgen decided to discontinue study because of a business decision and not because of safety reasons
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571828, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03571828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*